MetaCap

X4 Pharmaceuticals Inc. (XFOR)

NASDAQ: XFORHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

3.00+0.04 (+1.35%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

XFOR stock chart

Technical analysis

Key statistics

All statistics
Market cap
$306.34M
52-week range
2.43 – 4.83
Day range
2.89 – 3.06
Volume / Avg
1.83M / 877.70K
Beta
—

52-week range

$2.43$4.83

XFOR stock today

Shares of X4 Pharmaceuticals (XFOR) finished higher on Nov 20 at $3.00, a gain of 1.35% or $0.04 per share, versus the S&P 500's 3.70% decline. Volume was 2.1x the average at 1.83M shares, a sign of unusually heavy trading. Shares are 37.9% below their 52-week high of $4.83, set on Mar 10, 2026 and 23.5% above the 52-week low of $2.43, in the middle of the past year's range.

XFOR is down 25.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 20.0%. X4 Pharmaceuticals trades at 5.5x its trailing twelve-month earnings per share of $0.55.

Summary generated from market data by MetaCap's automated system. Methodology

About X4 Pharmaceuticals

Company profile

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Headquarters
Boston, MA
Employees
45
IPO year
2017

Financial highlights

Full financials

In fiscal 2025, X4 Pharmaceuticals generated $6.5 million in revenue, up 150.0% from fiscal 2024, its 2nd consecutive year of revenue growth. X4 Pharmaceuticals reported a net loss of $79.2 million, compared with a loss of $37.5 million a year earlier. Gross margin was 11.4% (down from 69.3%) and operating margin -1336.7%.

X4 Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$6.50M$2.60M$0$0$0
Growth+150.00%———-100.00%
Net income$-79.20M$-37.45M$-101.17M$-93.87M$-88.70M
EPS (diluted)$-1.87$-5.59$-17.07$-1.52$-3.99

Analyst forecast

Forecast

Consensus (5 analysts)

strong_buy

Avg. price target

$11.60+286.67%

  • Strong buy 0
  • Buy 5
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $10.00High $13.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-0.16 vs $-0.19
Surprise
+15.79%

XFOR news

All XFOR news

X4 Pharmaceuticals peers

Health Care sector
XFOR peer companies
CompanyPrice% ChgMarket capCompare
TRXBTRex Bio Inc.10.32+6.12%$296.95Mvs XFOR
SLBTSL Science Holding Limited0.55-3.36%$308.42Mvs XFOR
DTILPrecision BioSciences Inc.7.40+7.09%$282.46Mvs XFOR
CCCCC4 Therapeutics Inc.2.48+1.64%$325.67Mvs XFOR
AGENAgenus Inc.5.97-2.77%$270.12Mvs XFOR
KYTXKyverna Therapeutics Inc.4.26-2.52%$269.33Mvs XFOR
AGMBAgomAb Therapeutics NV ADR5.45-3.02%$268.40Mvs XFOR
OCGNOcugen Inc.0.7679+4.79%$260.55Mvs XFOR

Indexes, lists and sector

X4 Pharmaceuticals stock FAQ

What is X4 Pharmaceuticals's stock price today?

XFOR last traded at $3.00 as of Nov 20, 4:00 PM EST, up 1.35% on the day. Prices are delayed at least 15 minutes.

Does X4 Pharmaceuticals pay a dividend?

No. X4 Pharmaceuticals does not currently pay a regular cash dividend.

What is XFOR's P/E ratio?

XFOR trades at a trailing P/E ratio of 5.45.

Has XFOR ever split its stock?

Yes. The most recent XFOR stock split was a 1-for-30 split on Apr 28, 2025, one of 2 splits on record.

What is the XFOR 52-week high?

The 52-week high for XFOR is $4.83 and the 52-week low is $2.43. The stock is currently 37.9% below its high.

Compare XFOR